{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:44:59Z","timestamp":1772297099177,"version":"3.50.1"},"reference-count":19,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,11]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Immune checkpoint inhibitors have revolutionised cancer therapy in the past decade. Although they have been indicated to treat a diverse range of malignant neoplasms, they are also associated with various immune-related adverse effects. We report the case of a 74-year-old man with a history of urothelial carcinoma who had atezolizumab-induced myocarditis and myositis resulting in acute hypercapnic respiratory failure, despite the discontinuation of atezolizumab and aggressive treatment with corticosteroids. This case highlights the importance of a multidisciplinary approach for early diagnosis and treatment of immune-related adverse events. Physicians must be aware of the risks associated with immune checkpoint inhibitors and have a basic knowledge regarding their management.<\/jats:p>","DOI":"10.1136\/bcr-2020-236357","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T14:02:31Z","timestamp":1607522551000},"page":"e236357","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-9228","authenticated-orcid":false,"given":"Mary","family":"Sessums","sequence":"first","affiliation":[{"name":"Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siva","family":"Yarrarapu","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod K","family":"Guru","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devang K","family":"Sanghavi","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"2025082707333695000_13.12.e236357.1","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1212\/CON.0000000000000807","article-title":"Botulism, and immune checkpoint Inhibitor-Related myasthenia gravis","volume":"25","author":"Guidon","year":"2019","journal-title":"Continuum"},{"key":"2025082707333695000_13.12.e236357.2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025082707333695000_13.12.e236357.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025082707333695000_13.12.e236357.4","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.lpm.2018.10.009","article-title":"Neuromuscular complications of immune checkpoint inhibitors","volume":"47","author":"Psimaras","year":"2018","journal-title":"Presse Med"},{"key":"2025082707333695000_13.12.e236357.5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"2025082707333695000_13.12.e236357.6","first-page":"2","article-title":"Management of myasthenia gravis without significant exacerbation during nivolumab therapy for metastatic melanoma: a case report and review of literature","volume":"2","author":"Agrawal","year":"2019","journal-title":"Annals of Clinical Oncology"},{"key":"2025082707333695000_13.12.e236357.7","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1016\/j.clinph.2016.09.012","article-title":"Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized myasthenia gravis","volume":"127","author":"Liik","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"2025082707333695000_13.12.e236357.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124"},{"key":"2025082707333695000_13.12.e236357.9","doi-asserted-by":"crossref","DOI":"10.1097\/01.ccm.0000528605.84679.eb","article-title":"Myasthenia gravis crisis complicating anti-PD-L1 CancerImmunotherapy","volume":"46","author":"Chae","year":"2018","journal-title":"Crit Care Med"},{"key":"2025082707333695000_13.12.e236357.10","article-title":"De novo myasthenia gravis induced by Atezolizumab in a patient with urothelial carcinoma","volume":"11","author":"Thakolwiboon","year":"2019","journal-title":"Cureus"},{"key":"2025082707333695000_13.12.e236357.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.05.006"},{"key":"2025082707333695000_13.12.e236357.12","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000597"},{"key":"2025082707333695000_13.12.e236357.13","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1097\/MJT.0000000000000968","article-title":"Atezolizumab induced myocarditis on a background of cardiac amyloidosis","volume":"26","author":"Gupta","year":"2019","journal-title":"Am J Ther"},{"key":"2025082707333695000_13.12.e236357.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.033"},{"key":"2025082707333695000_13.12.e236357.15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025082707333695000_13.12.e236357.16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"key":"2025082707333695000_13.12.e236357.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025082707333695000_13.12.e236357.18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2025082707333695000_13.12.e236357.19","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-236357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:33:45Z","timestamp":1756305225000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-236357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,9]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bcr-2020-236357"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-236357","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}